Release
📈 Stocks
Eisai and Biogen Present New Lecanemab Data Showing 41% Decline Reduction
(just now)
New data from the Clarity AD substudy shows lecanemab effectively slows clinical decline in patients with α-synuclein co-pathology, a subgroup associated with…